{"id":357101,"date":"2026-05-07T15:47:11","date_gmt":"2026-05-07T14:47:11","guid":{"rendered":"https:\/\/www.herbalreality.com\/?post_type=condition&p=357101"},"modified":"2026-05-07T15:51:51","modified_gmt":"2026-05-07T14:51:51","slug":"depression","status":"publish","type":"condition","link":"https:\/\/www.herbalreality.com\/condition\/depression\/","title":{"rendered":"Depression"},"content":{"rendered":"\n

Characterised by low mood, anhedonia and other cognitive, emotional and behavioural symptoms, depression is a prevalent mood disorder that can be supported with herbs and holistic care.<\/em><\/p>\n\n\n\n

Understanding depression<\/h2><\/path><\/svg><\/span><\/div>
\n

Depression, clinically termed major depressive disorder, is a complex and multifactorial mood disorder characterised by persistent low mood, anhedonia (loss of interest or pleasure), and a range of cognitive, emotional and somatic disturbances (1). It extends beyond transient sadness, representing a pathological state that significantly impairs daily functioning, quality of life and interpersonal relationships. <\/p>\n\n\n\n

\"Depression\"<\/figure>\n\n\n\n

Core diagnostic features include feelings of hopelessness, low self-worth, fatigue, impaired concentration, sleep disturbances and changes in appetite (2). From a biomedical perspective, depression is increasingly understood as a systemic condition involving neurochemical, endocrine, inflammatory and psychosocial dysregulation rather than a purely \u2018chemical imbalance\u2019 (1,3).\u00a0<\/p>\n\n\n\n

Under the umbrella of unipolar depressive disorders, there is major depressive disorder, which is depression without a manic or hypomanic phase; dysthymic disorder, which consists of a pattern of chronic, ongoing mild depressive symptoms that are less severe than major depression; and seasonal affective disorder (SAD), which is depression or depressive symptoms related to seasonal changes (4,5). <\/p>\n\n\n\n

Depression is a leading contributor to global disease burden. Current estimates suggest a global prevalence of approximately 5% (6). It is recognised as one of the leading causes of years lived with disability worldwide and is associated with increased mortality, including suicide risk (7). In 2022, the proportion of adults in the UK experiencing moderate to severe depressive symptoms had increased to 16%, up from 10% prior to the pandemic. <\/p>\n\n\n\n

Women report higher rates than men (19% compared to 14%), with young people aged 16\u201329 most affected (28%). The burden is unevenly distributed, with markedly higher prevalence among individuals with disability (35% versus 7% in non-disabled adults), those unable to work due to long-term illness (59%), and unpaid carers providing more than 35 hours of care per week (37%), emphasising clear disparities across different population groups (8).<\/p>\n\n\n\n

Up to 40% of patients do not respond adequately to conventional antidepressant therapies, highlighting the need for broader therapeutic strategies (9). The socioeconomic burden is substantial, encompassing healthcare costs, reduced productivity, and long-term disability (7).<\/p>\n<\/div><\/div>\n\n\n\n

How does depression work?<\/h2><\/path><\/svg><\/span><\/div>
\n
\"Causes<\/figure>\n\n\n\n

The monoamine hypothesis remains a key framework in understanding depression. Monoamine neurotransmitters like serotonin, noradrenaline and dopamine are central to mood regulation, motivation, cognition and stress response (1,3). Reduced serotonergic activity is associated with low mood, anxiety, and sleep disturbance, while noradrenergic dysfunction contributes to fatigue, impaired concentration and altered stress resilience. Dopamine dysregulation, particularly within reward pathways contributes to anhedonia, reduced motivation and diminished goal-directed behaviour (1,3). <\/p>\n\n\n\n

Monoamine imbalance arises through multiple interacting mechanisms. These include impaired synthesis due to nutrient deficiencies or chronic stress, increased reuptake or degradation via transporter proteins and the enzyme monoamine oxidase (MAO) and altered receptor sensitivity. Inflammation further disrupts monoamine pathways by diverting tryptophan metabolism away from serotonin production, while chronic activation of the hypothalamic\u2013pituitary\u2013adrenal (HPA) axis and elevated cortisol can impair neurotransmitter function (1,3).<\/p>\n\n\n\n

Neuroendocrine dysfunction also plays a role, as HPA axis hyperactivation with elevated cortisol levels and impaired stress adaptation contributes to hippocampal atrophy and mood dysregulation (1,3). Reduced levels of brain-derived neurotrophic factor (BDNF) are associated with impaired formation of new neurons and synaptic plasticity. There is emerging evidence showing that both pharmacological and herbal treatments can enhance BDNF expression (1).<\/p>\n\n\n\n

Inflammation and gut microbiota are also implicated in the pathophysiology of depression (10). Low-grade systemic inflammation, characterised by elevated cytokines like IL-6 or TNF-\u03b1, is increasingly implicated in depression. This inflammatory state influences neurotransmitter metabolism and neural function. Alterations in gut microbiota composition can affect mood through immune, neural, and metabolic pathways, affecting neurotransmitter production and contributing to inflammation (10,11).<\/p>\n<\/div><\/div>\n\n\n\n

Understanding the root causes<\/h2><\/path><\/svg><\/span><\/div>
\n

Depression arises from an interplay of biological, psychological and social factors.<\/p>\n\n\n\n